Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

BACKGROUND: In advanced breast cancer, multiple sequential lines of treatments are frequently applied. Pegylated liposomal doxorubicin (PLD) has a favourable toxicity profile and can be used in first or higher lines of therapy. PLD has demonstrated response activity even after prior anthracycline ex...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Fiegl, Michael, Mlineritsch, Brigitte, Hubalek, Michael, Bartsch, Rupert, Pluschnig, Ursula, Steger, Günther G
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2011
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3178544/
https://ncbi.nlm.nih.gov/pubmed/21864402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-373
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg